Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gout: full-pipeline trial registry
8 of 35 indexed Gout trials are currently recruiting.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 8 currently recruiting · #435 of 28,707 conditions by registered trial count
Gout: 35 US clinical trials tracked, 8 recruiting.
Gout is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is University of Alabama at Birmingham, running 4 of these trials.
Enrollment posture brief
Registry condition gout
OPEN 8 | RECR 23% | LATE 10 | EARLY 15 | RANK #435 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Atherosclerosis (23% recruiting · 70 trials)
Gout lists 8 open slots (23% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gout on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gout is recruiting below its size-band peers.
8 of 35 indexed trials (22.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gout trials is spread across many organizations.
University of Alabama at Birmingham accounts for 4 of 35 trials (11.4%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Gout enrolment sits around 87 participants.
Median target enrolment is 87 among the 35 trials that report a genuine target (sentinel values excluded). 19 of those (54.3%) plan for fewer than 100 participants.
-
Gout research is mostly interventional.
33 interventional and 2 observational studies make up this index (94.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Massachusetts General Hospital
NCT04875702
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Crystalys Therapeutics
NCT07089875
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Olatec Therapeutics
NCT05658575
Dose Response of Exercise for Arthritis Management
University of South Carolina
NCT06880653
Improving Gout Care After an ED Visit
University of Alabama at Birmingham
NCT06534554
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
Protalix
NCT07280156
Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
Massachusetts General Hospital
NCT07346079
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
Arthrosi Therapeutics
NCT07116746
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Arthrosi Therapeutics
NCT06846515
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
Arthrosi Therapeutics
NCT06439602
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
Amgen
NCT06229145
Gout in the ED and Improving Research Participation
University of Alabama at Birmingham
NCT04075903
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
Shanton Pharma Pte.
NCT05690204
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
InventisBio Co.
NCT05665699
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
Shanton Pharma Pte.
NCT06729853
Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout
Attune Health Research
NCT04125459
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Brigham and Women's Hospital
NCT04746989
Virtual Gout Clinic
University of Alabama at Birmingham
NCT02790463
Combining Lesinurad With Allopurinol in Inadequate Responders
Ardea Biosciences
NCT01493531
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Savient Pharmaceuticals
NCT00325195
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
Savient Pharmaceuticals
NCT01356498
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
BioCryst Pharmaceuticals
NCT00985127
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
Selecta Biosciences
NCT02648269
Novel Methods for Ascertainment of Gout Flares -A Pilot Study
University of Alabama at Birmingham
NCT02855437
The Diet Gout Trial
Johns Hopkins University
NCT03569020
Mild, Moderate and Severe Renal Impairment Study
Ardea Biosciences
NCT02219516
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
LG Chem
NCT03927677
NSAID Drug Interaction Study
Ardea Biosciences
NCT01884272
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
LG Chem
NCT04139824
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
Selecta Biosciences
NCT02464605
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Urica Therapeutics
NCT06056570
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
BioCryst Pharmaceuticals
NCT01407874
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
Amgen
NCT03635957
Pharmacokinetics and Pharmacodynamics of Anthocyanins
Rutgers, The State University of New Jersey
NCT03650140
UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
University of California, Los Angeles
NCT06187519
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 7 |
| Phase 3 | 6 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Gout records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gout trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gout page
35 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Gout trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Alabama at Birmingham sponsors the most Gout trials on record, review their full trial history before evaluating a specific study. See University of Alabama at Birmingham's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gout condition card totals 35 registered trials; most-linked intervention Allopurinol; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.